<DOC>
	<DOCNO>NCT01965977</DOCNO>
	<brief_summary>High-intermediate high risk IPI long-term chance cure range 50 % patient DLBCL treat R-CHOP . These high risk patient consider additional new treatment standard R-CHOP investigational approach context clinical trial design ensure potentially curative therapy . Bortezomib show activity vitro DLBCL-derived cell line . Single-agent bortezomib chemotherapy combine bortezomib feasible follicular , mantle cell , marginal zone lymphoma DLBCL manageable toxicity . Bortezomib enhance activity chemotherapy non-GCB GCB DLBCL , provide rational therapeutic approach base genetically distinct DLBCL subtypes . High CR/CRu rate bortezomib standard R-CHOP suggests may good backbone additional maintenance lead durable response . However , study bortezomib maintenance therapy treat R-CHOP high risk patient DLBCL . So applied additional bortezomib maintenance therapy order ass improve efficacy survival rate high risk patient non-GCB DLBCL confirm CR treat R-CHOP .</brief_summary>
	<brief_title>Bortezomib Maintenance High Risk DLBCL</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>1 . Newly histologically confirm CD20 positive diffuse large Bcell lymphoma NonGCB type include 2 . High intermediate high risk IPI risk , Bulky mass ≥ 10cm diagnosis 3 . Complete response confirm six eight cycle RCHOP chemotherapy CT scan confirm negative PETCT base Revised International Workshop Criteria . 4 . Additional surgery radiotherapy accept 5 . Age ≥ 20 6 . Performance status ( ECOG ) ≤ 2 7 . Adeqaute renal function : Cr &lt; 2.5 mg/dL 8 . Adeqaute liver function : Transaminase ( AST/ALT ) &lt; 3 x upper normal value UNV ) Bilirubin &lt; 1.5 x UNV Alkaline phosphatase &lt; 5 xUNV 9 . Adeqaute BM function : ANC &gt; 1,000/uL platelet &gt; 75,000/uL hemoglobin &gt; 9.0 g/dL 10 . Written Informed consent 1 . Tumor response 68 cycle CTx &lt; CR 2 . Consider stem cell transplantation 3 . Central nervous system ( CNS ) metastases 4 . Pregnant lactate woman , patient childbearing potential employ adequate contraception 5 . Other serious illness medical condition A. Unstable cardiac disease despite treatment , myocardial infarction within 6 month prior study entry B . History significant neurologic psychiatric disorder include dementia seizure C. Active uncontrolled infection 6 . Any malignancy within past 5 year except curatively treat non melanoma skin cancer situ carcinoma cervix uterus . 7 . Prior history allegic reaction study treatment drug 8 . Peripheral neuropathy grade 2 bad 9 . DLBCL testis primary mediastinal DLBCL</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>